Sumitomo Mitsui DS Asset Management Company Ltd Boosts Stake in DexCom, Inc. (NASDAQ:DXCM)

Sumitomo Mitsui DS Asset Management Company Ltd increased its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 0.8% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 36,296 shares of the medical device company’s stock after buying an additional 295 shares during the quarter. Sumitomo Mitsui DS Asset Management Company Ltd’s holdings in DexCom were worth $4,504,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Winslow Capital Management LLC purchased a new position in shares of DexCom during the third quarter worth approximately $173,120,000. Vaughan Nelson Investment Management L.P. grew its position in DexCom by 16,943.0% during the 3rd quarter. Vaughan Nelson Investment Management L.P. now owns 1,459,730 shares of the medical device company’s stock worth $136,193,000 after purchasing an additional 1,451,165 shares during the last quarter. Westfield Capital Management Co. LP increased its stake in DexCom by 79.3% in the third quarter. Westfield Capital Management Co. LP now owns 1,847,865 shares of the medical device company’s stock valued at $172,406,000 after purchasing an additional 817,351 shares during the period. TimesSquare Capital Management LLC raised its holdings in shares of DexCom by 11,359.1% in the third quarter. TimesSquare Capital Management LLC now owns 733,380 shares of the medical device company’s stock valued at $68,424,000 after buying an additional 726,980 shares during the last quarter. Finally, Sands Capital Management LLC raised its holdings in shares of DexCom by 4.3% in the third quarter. Sands Capital Management LLC now owns 13,660,670 shares of the medical device company’s stock valued at $1,274,541,000 after buying an additional 557,543 shares during the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on DXCM shares. StockNews.com upgraded DexCom from a “hold” rating to a “buy” rating in a research report on Wednesday, April 3rd. Citigroup upped their price target on DexCom from $148.00 to $161.00 and gave the stock a “buy” rating in a research note on Wednesday, April 3rd. Royal Bank of Canada started coverage on shares of DexCom in a research report on Tuesday, March 12th. They issued an “outperform” rating and a $165.00 price objective on the stock. UBS Group boosted their price objective on shares of DexCom from $153.00 to $163.00 and gave the company a “buy” rating in a research note on Wednesday, April 10th. Finally, Raymond James lifted their target price on shares of DexCom from $147.00 to $151.00 and gave the company a “strong-buy” rating in a report on Tuesday, January 23rd. Two investment analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $141.40.

Insider Activity at DexCom

In other DexCom news, EVP Matthew Vincent Dolan sold 1,990 shares of the firm’s stock in a transaction on Monday, April 15th. The stock was sold at an average price of $137.81, for a total transaction of $274,241.90. Following the completion of the transaction, the executive vice president now owns 42,377 shares of the company’s stock, valued at $5,839,974.37. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, EVP Matthew Vincent Dolan sold 1,990 shares of the company’s stock in a transaction that occurred on Monday, April 15th. The shares were sold at an average price of $137.81, for a total transaction of $274,241.90. Following the transaction, the executive vice president now owns 42,377 shares of the company’s stock, valued at $5,839,974.37. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Kevin R. Sayer sold 49,633 shares of the business’s stock in a transaction on Monday, April 8th. The shares were sold at an average price of $138.30, for a total value of $6,864,243.90. Following the completion of the transaction, the chief executive officer now owns 283,893 shares of the company’s stock, valued at $39,262,401.90. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 189,375 shares of company stock valued at $25,530,859. 0.41% of the stock is owned by corporate insiders.

DexCom Trading Up 0.6 %

Shares of DXCM stock opened at $131.52 on Tuesday. The stock has a market cap of $50.70 billion, a P/E ratio of 100.40, a P/E/G ratio of 2.25 and a beta of 1.20. The company has a quick ratio of 2.48, a current ratio of 2.84 and a debt-to-equity ratio of 1.18. DexCom, Inc. has a fifty-two week low of $74.75 and a fifty-two week high of $142.00. The business has a fifty day simple moving average of $129.81 and a 200-day simple moving average of $117.38.

DexCom (NASDAQ:DXCM) last posted its earnings results on Thursday, February 8th. The medical device company reported $0.50 earnings per share for the quarter, beating the consensus estimate of $0.43 by $0.07. The firm had revenue of $1.03 billion during the quarter, compared to the consensus estimate of $1.02 billion. DexCom had a net margin of 14.95% and a return on equity of 28.31%. The firm’s revenue for the quarter was up 26.9% on a year-over-year basis. During the same period last year, the firm posted $0.34 EPS. On average, analysts forecast that DexCom, Inc. will post 1.76 earnings per share for the current fiscal year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.